Supernus Pharmaceuticals, Inc.
SUPN
$50.53
$1.162.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 776.83M | 718.95M | 681.54M | 665.13M | 668.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 776.83M | 718.95M | 681.54M | 665.13M | 668.00M |
| Cost of Revenue | 178.82M | 158.68M | 162.59M | 160.88M | 161.97M |
| Gross Profit | 598.01M | 560.27M | 518.95M | 504.24M | 506.03M |
| SG&A Expenses | 456.64M | 424.31M | 381.48M | 351.76M | 343.11M |
| Depreciation & Amortization | 95.31M | 89.46M | 83.17M | 78.34M | 77.63M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 752.89M | 694.56M | 649.36M | 613.09M | 608.89M |
| Operating Income | 23.95M | 24.39M | 32.18M | 52.04M | 59.11M |
| Income Before Tax | -49.15M | -49.03M | -20.73M | 82.16M | 91.80M |
| Income Tax Expenses | -20.13M | -10.48M | -1.62M | 17.67M | 29.88M |
| Earnings from Continuing Operations | -29.02 | -38.55 | -19.12 | 64.50 | 61.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.02M | -38.55M | -19.12M | 64.50M | 61.91M |
| EBIT | 23.95M | 24.39M | 32.18M | 52.04M | 59.11M |
| EBITDA | 121.26M | 115.96M | 117.57M | 132.72M | 139.16M |
| EPS Basic | -0.51 | -0.68 | -0.33 | 1.16 | 1.12 |
| Normalized Basic EPS | 0.39 | 0.42 | 0.54 | 0.79 | 0.86 |
| EPS Diluted | -0.51 | -0.68 | -0.34 | 1.15 | 1.11 |
| Normalized Diluted EPS | 0.39 | 0.42 | 0.53 | 0.78 | 0.85 |
| Average Basic Shares Outstanding | 227.57M | 225.79M | 223.91M | 222.50M | 221.46M |
| Average Diluted Shares Outstanding | 228.19M | 226.40M | 225.53M | 224.99M | 224.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |